ArriVent BioPharma, Inc. - AVBP
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 06, 2026 | SCHEDULE 13G/A | FMR LLC | 6.8% | 3,016,132 | View |
| May 06, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 6.8% | 3,016,132 | View |
| Mar 05, 2026 | SCHEDULE 13G/A | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.1% | 1,696,752 | View |
| Mar 05, 2026 | SCHEDULE 13G/A | Sofinnova Management XI, L.P. ("SM XI LP") | 4.1% | 1,696,752 | View |
| Mar 05, 2026 | SCHEDULE 13G/A | Sofinnova Management XI, L.L.C. ("SM XI LLC") | 4.1% | 1,696,752 | View |
| Mar 05, 2026 | SCHEDULE 13G/A | Dr. James I. Healy ("Healy") | 4.1% | 1,696,752 | View |
| Mar 05, 2026 | SCHEDULE 13G/A | Dr. Maha Katabi ("Katabi") | 4.1% | 1,696,752 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Hillhouse Investment Management, Ltd. | 9.5% | 3,929,117 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | INFINITUM ASSET MANAGEMENT, LLC | 9.9% | 4,123,923 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Infinitum Partners GP, LLC | 9.9% | 4,123,923 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Infinitum Cayman Master, Ltd. | 9.9% | 4,123,923 | View |
| Jan 30, 2026 | SCHEDULE 13G/A | The Vanguard Group | 4.52% | 1,869,266 | View |
| Jan 21, 2026 | SCHEDULE 13G | BlackRock, Inc. | 5.6% | 2,319,341 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.